Free Trial
NASDAQ:INBX

Inhibrx 5/8/2023 Earnings Report

Inhibrx logo
$12.36 +0.49 (+4.09%)
As of 09:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inhibrx EPS Results

Actual EPS
-$1.12
Consensus EPS
-$0.84
Beat/Miss
Missed by -$0.28
One Year Ago EPS
N/A

Inhibrx Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.30 million
Beat/Miss
Missed by -$280.00 thousand
YoY Revenue Growth
N/A

Inhibrx Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Inhibrx's Q4 2024 earnings is scheduled for Monday, June 16, 2025

Conference Call Resources

Inhibrx Earnings Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Inhibrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx and other key companies, straight to your email.

About Inhibrx

Inhibrx (NASDAQ:INBX), a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

View Inhibrx Profile

More Earnings Resources from MarketBeat